Lupin signs multiple agreements for marketing NaMuscla in EU Territories
On Wednesday, Lupin Limited informed the bourses that it has signed agreements with three companies namely Cresco Pharma B.V, Exeltis Healthcare S.L and Macure Pharma ApS with an objective of commercialization of its orphan drug NaMuscla (mexiletine) in EU territories.
NaMuscla is indicated for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. NDM disorders are a group of uncommon, genetic neuromuscular disorders which render the muscles unable to relax following voluntary contraction.
Intake of NaMuscla results in a noteworthy improvement in patient quality-of-life and other functional and clinical outcomes. It is the first and sole licensed product for this indication. It was in December 2018 that the company received authorization to market this drug.
In line with the terms of the arrangement, Cresco Pharma B.V will commercialize the drug in the Netherlands; Exeltis Healthcare S.L will commercialize NaMuscla in Spain and Portugal and Macure Pharma ApS will proceed to do so in Nordic countries. Lupin Limited will continue commercializing NaMuscla in Germany and UK and has plans to launch the product in Austria and France in the latter part of this year.
The stock was trading at Rs 868.80, at 3.30 pm on Wednesday, down by 0.24 per cent or Rs 2.10 per share. The 52-week high is recorded at Rs 919 and the 52-week low is Rs 505 on BSE.